More recently, the long-term assessment of anti-TNF-α inhibitor treatment to individuals diagnosed with metabolic syndrome has been shown to increase adiponectin levels, confirming a role for TNF-α in obesity-related insulin resistance in humans [12]. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.